We are live on ! Find out more
ADCT icon

ADC Therapeutics

41 hedge funds and large institutions have $1B invested in ADC Therapeutics in 2020 Q2 according to their latest regulatory filings, with 41 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

30.48% more ownership

Funds ownership: 0%30.48% (+30%)

Holders
41
Holders Change
+41
Holders Change %
% of All Funds
0.84%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.08%
New
41
Increased
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change

ADCT Hedge Fund Activity: Q2 2020 in Review

41 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in ADC Therapeutics (ADCT) for Q2 2020, worth a combined $1B.

Buyers outnumbered sellers: 41 funds opened new ADCT positions and 0 closed out — a net gain of 41 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Redmile Group, opening a new position worth an estimated $210M.

  • 41 institutional investors held ADC Therapeutics (ADCT) as of Q2 2020, up from 0 in Q1 2020.
  • Funds reported $1B of ADC Therapeutics stock for Q2 2020.
  • 41 funds opened new ADC Therapeutics positions in Q2 2020 and 0 closed out, a net change of +41 holders.
  • The largest ADC Therapeutics buyer in Q2 2020 was Redmile Group, an estimated $210M added.

Based on aggregated 13F filings for Q2 2020.